Malignant Neoplasms of the Colon: Complete ICD-11 Coding Guide
1. Introduction
Malignant neoplasms of the colon represent one of the most prevalent types of cancer of the gastrointestinal tract worldwide, affecting millions of people annually. These neoplasms are primary malignant tumors that develop from the cells lining the colon, and can arise in any segment of this organ, from the cecum to the sigmoid.
The clinical importance of malignant neoplasms of the colon cannot be underestimated. It is a condition that presents high morbidity and mortality when not detected early, but also has an excellent prognosis when identified in early stages. The colon, being the longest portion of the large intestine, is particularly susceptible to the development of neoplastic lesions due to its function of water absorption and temporary storage of waste, which maintains prolonged contact between the intestinal mucosa and potentially carcinogenic substances.
From a public health perspective, malignant neoplasms of the colon represent a significant challenge. Population screening programs have demonstrated efficacy in early detection, allowing for more effective and less invasive therapeutic interventions. The economic impact of these neoplasms is considerable, involving costs with diagnosis, treatment, follow-up, and patient rehabilitation.
Correct coding of these neoplasms is absolutely critical for various aspects of medical care. It enables appropriate epidemiological registration, facilitating studies of prevalence and incidence, aids in planning public health resources, ensures appropriate reimbursement of procedures, enables quality clinical research, and ensures continuity of care among different professionals and health institutions.
2. Correct ICD-11 Code
Code: 2B90
Description: Malignant neoplasms of the colon
Parent category: Malignant neoplasms of the large intestine
Official definition: Primary malignant neoplasms that arise in the colon.
This code belongs to the neoplasms chapter of ICD-11 and is specifically designated for primary malignant tumors that originate in the colon. It is fundamental to understand that this code refers exclusively to neoplasms that originally arise in the colon, not including metastases from other organs to the colon or neoplasms of other portions of the large intestine.
Code 2B90 is part of a well-structured hierarchical system in ICD-11, which allows adequate specificity without losing the ability to aggregate data for epidemiological purposes. The parent category encompasses all malignant neoplasms of the large intestine, while code 2B90 specifies the location in the colon, excluding the rectosigmoid junction, rectum, and appendix.
The correct use of this code requires histopathological confirmation of malignancy and clear identification that the primary origin of the tumor is in the colon. Medical documentation must contain information about the specific location within the colon (cecum, ascending colon, transverse colon, descending colon, or sigmoid), although code 2B90 encompasses all these locations.
3. When to Use This Code
Code 2B90 should be used in specific and well-defined clinical situations. Below, we present detailed practical scenarios where this code is appropriate:
Scenario 1: Adenocarcinoma of the ascending colon diagnosed by colonoscopy A 65-year-old patient presents with unexplained iron deficiency anemia and progressive fatigue. Colonoscopy is performed and identifies an ulcerated mass in the ascending colon. Biopsies are collected and histopathological examination confirms moderately differentiated adenocarcinoma. In this case, code 2B90 is appropriate because it is a primary malignant neoplasm of the colon with histological confirmation.
Scenario 2: Carcinoma of the cecum detected in a screening program During screening colonoscopy in an asymptomatic 58-year-old patient, a polypoid lesion measuring 3 centimeters is identified in the cecum. Polypectomy is performed and histopathological analysis reveals adenocarcinoma invading the submucosa. Code 2B90 is appropriate because the cecum is part of the colon and the neoplasm is primary to this location.
Scenario 3: Synchronous tumor of the transverse and descending colon A patient with a family history of colorectal cancer undergoes colonoscopy that identifies two distinct lesions: one in the transverse colon and another in the descending colon. Both biopsies confirm adenocarcinoma. Each lesion should be coded separately with 2B90, documenting the multiple primary sites.
Scenario 4: Local recurrence of adenocarcinoma of the sigmoid colon after previous resection A patient who underwent sigmoidectomy two years ago for adenocarcinoma presents with local recurrence confirmed by colonoscopy and biopsy. Code 2B90 remains appropriate because it is a recurrence of the primary neoplasm of the colon, and recurrence specifiers should be added when available in the coding system.
Scenario 5: Mucinous carcinoma of the descending colon with preoperative diagnosis A patient with altered bowel habits and hematochezia undergoes colonoscopy that reveals a stenotic lesion in the descending colon. Biopsy confirms mucinous adenocarcinoma. Prior to surgery, code 2B90 is used to document the primary neoplasm of the colon.
Scenario 6: Neoplasm of the colon diagnosed in surgical specimen During emergency surgery for intestinal obstruction, a tumor mass is identified in the transverse colon. Resection is performed and histopathological examination of the surgical specimen confirms invasive adenocarcinoma. Code 2B90 is appropriate even when histological diagnosis is established only after resection.
4. When NOT to Use This Code
It is fundamental to recognize situations where code 2B90 should not be used, avoiding coding errors that may compromise medical records and epidemiological data:
Neoplasms of the appendix: If the primary neoplasm is located in the appendix, the specific code for malignant neoplasms of the appendix (1892026854) should be used, not code 2B90. Although the appendix is technically an extension of the cecum, appendicular neoplasms have distinct biological characteristics and clinical behavior, justifying separate coding.
Neoplasms of the rectosigmoid junction: Tumors located at the rectosigmoid junction, defined as the transition area between the sigmoid and the rectum, should be coded as 2B91. This distinction is important because therapeutic approach and prognosis may differ.
Neoplasms of the rectum: Any primary malignant tumor of the rectum should be coded as 2B92, not 2B90. The rectum has specific anatomical and functional characteristics, and its treatment frequently involves different approaches than colonic neoplasms.
Metastases to the colon: When a tumor from another organ (lung, breast, ovary, for example) metastasizes to the colon, code 2B90 should not be used. In this case, the primary neoplasm is coded and a code for secondary metastasis is added.
Benign neoplasms of the colon: Adenomatous polyps, even with high-grade dysplasia, should not be coded as 2B90 if there is no evidence of malignant invasion. Only confirmed malignant neoplasms receive this code.
Unspecified location: When the documentation does not allow determination of whether the neoplasm is in the colon, rectum, or rectosigmoid junction, code 2B93 (malignant neoplasms of the large intestine, unspecified location) should be used instead of assuming colonic location.
5. Step-by-Step Coding Process
Step 1: Assess diagnostic criteria
The diagnostic confirmation of malignant neoplasm of the colon requires careful evaluation and adequate documentation. The first step is to verify whether there is histopathological or cytological confirmation of malignancy. Ideally, the diagnosis should be established through endoscopic biopsy during colonoscopy or, in some cases, through examination of the resected surgical specimen.
Essential diagnostic instruments include colonoscopy with biopsy, which is the gold standard for diagnosis. Imaging studies such as computed tomography or magnetic resonance imaging can identify the lesion, but do not replace histological confirmation. The anatomopathological report should describe the histological type (adenocarcinoma, mucinous carcinoma, signet ring cell carcinoma, etc.), degree of differentiation, and depth of invasion.
It is necessary to confirm that the neoplasm is primary to the colon, not a metastasis from another organ. Clinical history, imaging studies, and histopathological characteristics help in this differentiation. Immunohistochemical markers may be useful in doubtful cases.
Step 2: Verify specifiers
After confirming the diagnosis of malignant neoplasm of the colon, additional characteristics that may influence treatment and prognosis should be documented. The specific location within the colon (cecum, ascending, transverse, descending, or sigmoid) should be clearly documented, even though all are coded as 2B90.
TNM staging should be recorded when available, including tumor size (T), lymph node involvement (N), and presence of distant metastases (M). Although code 2B90 does not specify stage, this information is crucial for therapeutic planning and should be included in the documentation.
Relevant histopathological characteristics include histological type, degree of differentiation, presence of lymphovascular or perineural invasion, and status of molecular markers such as microsatellite instability (MSI) or specific mutations. This information, although it does not change the primary code, is essential for adequate treatment.
Step 3: Differentiate from other codes
2B91 - Malignant neoplasms of the rectosigmoid junction: The fundamental difference lies in anatomical location. The rectosigmoid junction is defined as the transition zone between the sigmoid and the rectum, usually located approximately 15-16 centimeters from the anal margin. If the tumor is centered in this transition region, use 2B91. If it is clearly in the sigmoid, above this junction, use 2B90.
2B92 - Malignant neoplasms of the rectum: The rectum begins approximately 15 centimeters from the anal margin and extends to the rectosigmoid junction. Tumors located in this segment receive code 2B92. The distinction is important because treatment of rectal cancer frequently involves neoadjuvant radiotherapy, whereas colon cancer generally does not. Endoscopy with precise measurement of the distance from the anal margin is essential for this differentiation.
2B93 - Malignant neoplasms of the large intestine, unspecified location: This code should be used only when the documentation is insufficient to determine whether the neoplasm is in the colon, rectum, or rectosigmoid junction. Whenever possible, additional information should be sought to allow more specific coding with 2B90, 2B91, or 2B92.
Step 4: Required documentation
Adequate documentation is fundamental for correct coding and continuity of care. The medical record should contain:
Checklist of mandatory information:
- Histopathological confirmation of malignancy with specific histological type
- Precise location within the colon (specific segment)
- Date of initial diagnosis
- Diagnostic method used (colonoscopy with biopsy, surgical specimen analysis, etc.)
- Clinical and/or pathological staging when available
- Presence or absence of metastases
- Prior treatments if applicable
- Patient performance status
How to record adequately: The medical record should include complete colonoscopy reports with detailed description of the lesion, distance from the anal margin, endoscopic appearance, and number of biopsies performed. The complete anatomopathological report should be attached, including histological type, degree of differentiation, and depth of invasion. Staging studies (computed tomography, magnetic resonance imaging, PET-CT) should be documented with their respective dates and results.
6. Complete Practical Example
Clinical Case
A 62-year-old male patient seeks medical care with a complaint of altered bowel habits for four months, characterized by alternating episodes of constipation and diarrhea. He also reports unintentional weight loss of approximately 8 kilograms during the same period and occasional episodes of rectal bleeding mixed with stool. He denies severe abdominal pain but reports discomfort in the left lower quadrant. Positive family history for colorectal cancer (father diagnosed at age 70).
On physical examination, the patient appears emaciated, with pale mucous membranes (+/4+), slightly distended abdomen, non-tender on superficial palpation, with a palpable mass in the left iliac fossa, mobile, with hardened consistency. Digital rectal examination without abnormalities, empty ampulla.
Laboratory tests reveal hemoglobin of 9.5 g/dL, decreased mean corpuscular volume, low ferritin, consistent with iron deficiency anemia. Tumor marker CEA (carcinoembryonic antigen) elevated at 45 ng/mL.
Colonoscopy performed reveals a vegetating, ulcerated lesion, friable to forceps touch, occupying approximately 60% of the circumference of the descending colon, located 35 centimeters from the anal margin. Multiple biopsies are obtained. The colonoscope is advanced to the cecum, with no other synchronous lesions identified. Histopathological examination of the biopsies confirms moderately differentiated, invasive adenocarcinoma.
Computed tomography of the abdomen and chest for staging reveals wall thickening in the descending colon, three enlarged regional lymph nodes (larger than 1 centimeter) and absence of hepatic or pulmonary metastases. Suggested clinical staging: T3N1M0.
Step-by-Step Coding
Criteria analysis:
- Confirmation of malignancy: Present - histopathological examination confirms adenocarcinoma
- Primary location in the colon: Confirmed - tumor located in the descending colon
- Exclusion of other locations: The tumor is not at the rectosigmoid junction (located 35 cm from the anal margin, well above the 15-16 cm that define the beginning of the rectum), is not in the rectum, is not in the appendix
- Exclusion of metastasis: This is a primary neoplasm of the colon, not a metastasis from another organ
Code selected: 2B90 - Malignant neoplasms of the colon
Complete justification:
Code 2B90 is the most appropriate for this case because all criteria for primary malignant neoplasm of the colon are present. The location in the descending colon, 35 centimeters from the anal margin, places the tumor clearly in the colon, excluding the rectosigmoid junction (2B91) and rectum (2B92). Histopathological confirmation of adenocarcinoma establishes the malignant nature, differentiating from benign lesions. The absence of a history of primary neoplasm in another organ and the typical endoscopic and histological characteristics confirm this to be a primary tumor of the colon.
Applicable complementary codes:
In addition to the primary code 2B90, other codes may be relevant for complete documentation:
- Code for TNM staging when available in the system
- Code for iron deficiency anemia secondary to neoplasm
- Codes for procedures performed (colonoscopy, biopsy)
- Code for family history of colorectal neoplasm, if the system allows
7. Related Codes and Differentiation
Within the Same Category
2B91: Malignant neoplasms of the rectosigmoid junction
The differentiation between 2B90 and 2B91 is based exclusively on the precise anatomical location of the tumor. The rectosigmoid junction is an anatomical transition zone located approximately 15-16 centimeters from the anal margin, where the sigmoid loses its taeniae coli and transitions to the structure of the rectum.
When to use 2B91 versus 2B90: Use 2B91 when the tumor is centered at the rectosigmoid junction, even if it extends into the adjacent sigmoid or rectum. Use 2B90 when the tumor is clearly in the sigmoid, above this transition zone. Precise endoscopic measurement of the distance from the anal margin is crucial. Tumors located above 16 centimeters from the anal margin are usually coded as 2B90, while those between 15-16 centimeters may be 2B91.
2B92: Malignant neoplasms of the rectum
The rectum is defined as the segment of the large intestine that extends from the rectosigmoid junction (approximately 15-16 cm from the anal margin) to the pectinate line. This distinction is not merely anatomical but has significant therapeutic implications.
When to use 2B92 versus 2B90: Use 2B92 when the tumor is located below 15 centimeters from the anal margin, in the rectum proper. The main difference lies in the therapeutic approach: rectal neoplasms frequently receive neoadjuvant radiotherapy combined with chemotherapy, followed by surgery, while colon neoplasms are usually treated with primary surgery followed by adjuvant chemotherapy when indicated. Pelvic magnetic resonance imaging is frequently used for staging of rectal tumors but is not routine for colon tumors.
2B93: Malignant neoplasms of the large intestine, unspecified location
This code represents a residual category that should be used with caution and only when absolutely necessary.
When to use 2B93 versus 2B90: Use 2B93 only when the available documentation is insufficient to determine whether the neoplasm is in the colon, rectum, or rectosigmoid junction. Situations that may justify 2B93 include: diagnosis based only on ascitic fluid cytology without colonoscopy, inadequate medical documentation that does not specify location, or cases where tumor extension is so extensive that it does not allow identification of the primary site. Whenever possible, additional information should be sought (colonoscopy reports, surgical reports, imaging studies) to allow more specific coding with 2B90.
Differential Diagnoses
Various conditions can clinically simulate malignant neoplasms of the colon and must be differentiated:
Complicated diverticular disease: Can present with a palpable mass and wall thickening on imaging studies, simulating neoplasm. Colonoscopy with biopsy is essential for differentiation.
Inflammatory bowel disease: Inflammatory strictures in Crohn disease or ulcerative colitis can simulate neoplasm. Patients with long-standing inflammatory bowel disease have increased risk of developing dysplasia and cancer, making endoscopic surveillance essential.
Ischemic colitis: Can cause segmental stricture that simulates neoplasm on imaging studies. Clinical history and endoscopic findings help with differentiation.
Intestinal endometriosis: In women, can cause mass and stricture in the sigmoid or rectum, simulating neoplasm. Biopsy is necessary for definitive diagnosis.
8. Differences with ICD-10
In ICD-10, malignant neoplasms of the colon were coded in category C18, with specific subdivisions for each colon segment:
- C18.0 Cecum
- C18.2 Ascending colon
- C18.3 Hepatic flexure
- C18.4 Transverse colon
- C18.5 Splenic flexure
- C18.6 Descending colon
- C18.7 Sigmoid colon
The main change in ICD-11 with code 2B90 is the consolidation of all these specific colon locations into a single main code, with the possibility of additional specification through code extensions when necessary. This approach simplifies initial coding while maintaining the ability to detail the specific location when relevant.
Another significant difference is the clearer hierarchical structure in ICD-11, where 2B90 is explicitly linked to the higher category of malignant neoplasms of the large intestine, facilitating navigation and understanding of relationships between codes. ICD-11 also offers better integration with electronic health record systems and greater international compatibility.
The practical impact of these changes includes greater ease of coding for health professionals, better aggregation of epidemiological data at national and international levels, and reduction of coding errors related to choosing among multiple anatomical subdivisions. However, health information systems need to be updated to incorporate the new ICD-11 structure.
9. Frequently Asked Questions
How is malignant neoplasm of the colon diagnosed?
The diagnosis requires histopathological confirmation, generally obtained through colonoscopy with biopsy. The procedure involves the introduction of a flexible colonoscope through the anus, allowing direct visualization of the colonic mucosa and collection of tissue fragments for microscopic analysis. In some cases, the diagnosis is established only after surgical resection, when examination of the surgical specimen reveals malignancy. Imaging studies such as computed tomography may suggest the diagnosis, but do not confirm it definitively. Tumor markers such as CEA may be elevated, but are not diagnostic by themselves.
Is treatment available in public health systems?
Treatment of malignant neoplasms of the colon is generally available in public health systems in many countries, although access and waiting times may vary. Treatment typically involves surgical resection of the affected colon segment with adequate oncologic margins and regional lymphadenectomy. Adjuvant chemotherapy is indicated in cases with lymph node involvement or high-risk features. Public health systems generally cover both surgical procedures and chemotherapy, although newer medications and immunotherapies may have limited availability in some locations.
How long does treatment last?
The duration of treatment varies according to staging and case complexity. Surgery is performed in a single procedure, with typical hospitalization of 5 to 10 days for postoperative recovery. When indicated, adjuvant chemotherapy generally lasts 6 months, with cycles administered every 2 or 3 weeks. Follow-up after curative treatment extends for at least 5 years, with periodic consultations, laboratory tests, and surveillance colonoscopies. Patients with advanced disease may require prolonged palliative treatment.
Can this code be used in medical certificates?
Yes, code 2B90 can and should be used in medical certificates when appropriate, especially to justify work absence or temporary or permanent disability. However, patient confidentiality and privacy issues should be considered. Some professionals prefer to use more generic terms in documents that will be seen by third parties, reserving specific codes for internal medical documentation. Medical privacy legislation varies between jurisdictions, and professionals should be familiar with local regulations.
What is the difference between colon neoplasm and colorectal neoplasm?
Colorectal neoplasm is a comprehensive term that includes both colon and rectal neoplasms. Code 2B90 refers specifically to neoplasms of the colon, excluding the rectum (2B92) and the rectosigmoid junction (2B91). This distinction is important because the treatment of colon cancer differs from the treatment of rectal cancer, particularly regarding the use of neoadjuvant radiotherapy. When documentation refers to "colorectal cancer" without specifying location, it may be necessary to seek additional information for accurate coding.
Do colon polyps always become cancer?
No, not all colon polyps become malignant. Adenomatous polyps have potential for malignant transformation, but this process generally takes years. Removal of polyps during colonoscopy (polypectomy) is an important preventive measure that significantly reduces the risk of cancer development. Hyperplastic polyps generally do not have significant malignant potential. Only when there is histopathological confirmation of malignancy (invasion beyond the mucosa) should code 2B90 be used.
Do patients with a family history of colon cancer need differentiated screening?
Yes, a family history of colorectal neoplasm, especially in first-degree relatives or diagnosis at a young age, increases individual risk and justifies earlier initiation and shorter intervals of screening. Hereditary syndromes such as familial adenomatous polyposis or Lynch syndrome require specific and intensive surveillance protocols. Genetic counseling may be appropriate for families with multiple cases or a pattern suggestive of hereditary syndrome.
What is the prognosis of malignant neoplasm of the colon?
The prognosis varies widely according to staging at diagnosis. Neoplasms detected at early stages (limited to the intestinal wall, without lymph node involvement) have an excellent prognosis with 5-year survival greater than 90% after appropriate treatment. Cases with lymph node involvement have intermediate prognosis, while metastatic disease has a more guarded prognosis. Additional factors that influence prognosis include histologic type, degree of differentiation, lymphovascular invasion, and molecular characteristics of the tumor. Regular follow-up after treatment is essential for early detection of recurrence.
Conclusion
Code 2B90 of ICD-11 for malignant neoplasms of the colon represents an essential tool for appropriate documentation, epidemiologic registration, and health planning. Correct coding requires clear understanding of diagnostic criteria, precise differentiation of related codes, and adequate documentation. Health professionals should be familiar with the nuances of this code to ensure accurate medical records and appropriate continuity of patient care.
External References
This article was prepared based on reliable scientific sources:
- 🌍 WHO ICD-11 - Malignant neoplasms of the colon
- 🔬 PubMed Research on Malignant neoplasms of the colon
- 🌍 WHO Health Topics
- 📊 Clinical Evidence: Malignant neoplasms of the colon
- 📋 Ministry of Health - Brazil
- 📊 Cochrane Systematic Reviews
References verified on 2026-02-04